ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Execs Bet Big as Market Wobbles

By ORTEX News · Edited by , Editor, ORTEX News1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

The boldest insider move this week came from ACS, the Spanish construction giant. CEO Florentino Perez Rodriguez filed on August 3rd, disclosing he bought 400,000 shares worth roughly $50.5 million across three consecutive days — July 29, 30, and 31. That kind of sustained, high-conviction buying from a chairman-CEO is rare. It signals strong personal confidence in the stock at current levels.

In the US, BSX CEO Michael Mahoney filed on August 5th showing a $9 million purchase on August 3rd. He picked up 186,240 Boston Scientific shares. C-suite buys of this size are attention-worthy — executives rarely spend personal capital unless they believe the market is undervaluing the company.

CSGP founder and CEO Andrew Florance also filed fresh buying. He disclosed a $2.5 million purchase of CoStar Group shares on August 4th.

On the selling side, ILMN saw a board-level seller. Keith Meister, an asset manager representing the board, filed a $33 million sale of Illumina shares on August 6th.

NEXT plc CEO Simon Wolfson disclosed selling £31.7 million worth of shares on August 7th — a significant liquidation for the UK retailer's chief.

The clearest cluster of buying pressure sits with the Adani Power group in India, where seven affiliated entities filed $2.77 billion in cumulative purchases on August 7th — though these are promoter-group disclosures rather than classic insider buys.

This is not financial advice.

Stocks in this article

How this article was generated

Generated
10 Aug 2026, 08:10
Prompt version
v1.0
Data sources
Institutional positioning

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.